Advertisement

Management of Restless Legs Syndrome

  • Mark J. Buchfuhrer
Chapter
  • 547 Downloads

Abstract

Due to developments in diagnosing and treating restless legs syndrome (RLS) over the past decade, there has been a marked increase in the awareness of RLS among both physicians and patients. In fact, it is estimated that 2 % of patients in primary care practices have RLS that is serious and disruptive enough to treat, with the number being diagnosed and treated expected to increase as awareness grows. This chapter aims to provide physicians with guidance to manage this large group of patients properly.

Keywords

Dopamine Agonist Ferric Carboxymaltose Impulse Control Disorder Gabapentin Enacarbil Granisetron Hydrochloride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237–46.CrossRefPubMedGoogle Scholar
  2. 2.
    Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG. Medical Advisory Board of the Willis-Ekbom Disease Foundation Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88:977–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2006;19:487–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep. 1998;21:371–7.PubMedGoogle Scholar
  5. 5.
    O’Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23:200–3.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang J, O’Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10:973–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Cho YW, Allen RP, Earley CJ. Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep Med. 2013;14:274–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12:906–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Burbank F, Buchfuhrer MJ, Kopjar B. Sleep improvement for restless legs syndrome patients. Part I: pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RLS symptoms. J Parkinsonism Restless Legs Syndrome. 2013;3:1–10.CrossRefGoogle Scholar
  10. 10.
    Burbank F, Buchfuhrer MJ, Kopjar B. Sleep improvement for restless legs syndrome patients. Part II: pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RLS symptoms. J Parkinsonism Restless Legs Syndrome. 2013;3:11–22.CrossRefGoogle Scholar
  11. 11.
    Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol. 1982;39:739.CrossRefPubMedGoogle Scholar
  12. 12.
    Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–13.PubMedGoogle Scholar
  13. 13.
    Maestri M, Fulda S, Ferini-Strambi L, Zucconi M, Marelli S, Staedler C, et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med. 2014;15:570–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Garcia-Borreguero D, Allen RP, Silber MH, Winkleman JW, Högl B, Bainbridge B, et al. White paper summary of recommendations for the prevention and treatment of RLS/WED augmentation. A combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. International Restless Legs Syndrome Study Group website. http://irlssg.org/wp-content/uploads/2015/05/Summary-of-recommendations-RLS-Augmentation-13Aug2015.pdf. Accessed 21 Jan 2016.
  15. 15.
    Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59:1573–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, Chen D. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol. 2011;34:8–16.CrossRefPubMedGoogle Scholar
  17. 17.
    Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, Miceli J, Knapp L, Allen RP. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37:635–43.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48:1378–88.CrossRefPubMedGoogle Scholar
  20. 20.
    Walters AS. Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome. Sleep Med. 2002;3:301–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20:345–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, RELOXYN Study Group, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry. 1999;60:241–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006;7:592–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Mitler MM, Browman CP, Menh SJ, Gujavarty K, Timms RM, et al. Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam. Sleep. 1986;9:385–92.PubMedGoogle Scholar
  26. 26.
    Allen RP, Barker PB, Horská A, Earley CJ. Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology. 2013;80:2028–34.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Monplaisi J, Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.CrossRefPubMedGoogle Scholar
  28. 28.
    Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12:431–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, et al. SP710 study group. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–20.Google Scholar
  31. 31.
    Picchietti DL, Hensley JG, Bainbridge JL, Lee KA, Manconi M, McGregor JA, International Restless Legs Syndrome Study Group (IRLSSG). Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev. 2015;22:64–77.CrossRefPubMedGoogle Scholar
  32. 32.
    Molnar MZ, Novak M, Mucsi I. Management of restless legs syndrome in patients on dialysis. Drugs. 2006;66:607–24.CrossRefPubMedGoogle Scholar
  33. 33.
    Picchietti DL, Bruni O, de Weerd A, Durmer JS, Kotagal S, Owens JA, Simakajornboon N, International Restless Legs Syndrome Study Group (IRLSSG). Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:1253–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment. Sleep Med. 2010;11:643–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Kurlan R, Richard IH, Deeley C. Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation. J Gen Intern Med. 2006;21:C1–4.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kurlan R, Rabin M. Augmentation in restless legs syndrome: poor response to sudden withdrawal of dopaminergic therapy. J Parkinsonism Restless Legs Syndrome. 2013;3:49–52.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Mark J. Buchfuhrer
    • 1
  1. 1.PIH Health Hospital - DowneyDowneyUSA

Personalised recommendations